Gariot P, Foliguet B, Drouin P, Barrat E, Genton P, Debry G
Atherosclerosis. 1986 Mar;59(3):257-62. doi: 10.1016/0021-9150(86)90120-6.
A morphometric study on liver biopsies from patients with primary hyperlipoproteinemia (IIa n = 4, IIb n = 7, IV n = 7) and in controls (n = 7) was performed by light and electron microscopy. We found hypertrophy of peroxisomes in all subjects with hyperlipoproteinemia. As none of our patients had been given lipid-lowering drugs, this increase in volume seems to be due to hyperlipoproteinemia. Hypertrophy of peroxisomes in hyperlipoproteinemia may constitute a response of the hepatocyte to a disturbed metabolic state. Alterations of peroxisomes in hyperlipoproteinemia may thus occur prior to any lipid-lowering therapy.
通过光学显微镜和电子显微镜对原发性高脂蛋白血症患者（IIa型4例，IIb型7例，IV型7例）及对照组（7例）的肝活检组织进行了形态计量学研究。我们发现所有高脂蛋白血症患者的过氧化物酶体均肥大。由于我们的患者均未接受过降脂药物治疗，这种体积增加似乎是由高脂蛋白血症引起的。高脂蛋白血症中过氧化物酶体的肥大可能是肝细胞对代谢紊乱状态的一种反应。因此，高脂蛋白血症中过氧化物酶体的改变可能在任何降脂治疗之前就已发生。
